Polar Capital Biotech I GBP Hdg Inc |
Performance History | 30/04/2024 |
Growth of 1,000 (EUR) |
Fund | 30.4 | 11.5 | -13.6 | 18.0 | 0.5 | |
+/-Cat | - | - | - | - | - | |
+/-Idx | - | - | - | - | - | |
Category: Other Equity | ||||||
Benchmarks: - |
Key Stats | ||
NAV 16/05/2024 | GBP 18.26 | |
Day Change | -0.46% | |
Morningstar Category™ | Other Equity | |
ISIN | IE00BFX4HX56 | |
Fund Size (Mil) 16/05/2024 | USD 1702.65 | |
Share Class Size (Mil) 16/05/2024 | GBP 44.02 | |
Max Initial Charge | 5.00% | |
Ongoing Charge 31/12/2023 | 1.12% |
Investment Objective: Polar Capital Biotech I GBP Hdg Inc |
The investment objective of the Fund is to preserve capital and achieve long term capital appreciation. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
David Pinniger 31/10/2013 | ||
Gareth Powell 31/10/2013 | ||
Inception Date 17/01/2018 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology NR USD | - |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Polar Capital Biotech I GBP Hdg Inc | 31/03/2024 |
|
|
Top 5 Holdings | Sector | % |
Regeneron Pharmaceuticals Inc | Healthcare | 6.38 |
Amgen Inc | Healthcare | 5.50 |
argenx SE | Healthcare | 4.92 |
Blueprint Medicines Corp | Healthcare | 4.33 |
Zealand Pharma A/S | Healthcare | 4.09 |
Increase Decrease New since last portfolio | ||
Polar Capital Biotech I GBP Hdg Inc |